COLL

Collegium Pharmaceutical, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · collegiumpharma.com

$34.58

Mkt Cap $1.1B

52w Low $26.72 32.7% of range 52w High $50.79

50d MA $35.86 200d MA $39.39

P/E (TTM) 17.3x

EV/EBITDA 5.4x

P/B 3.6x

Debt/Equity 3.1x

ROE 5.6%

P/FCF 4.5x

RSI (14) —

ATR (14) —

Beta 0.77

50d MA $35.86

200d MA $39.39

Avg Volume 503.7K

About

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to requir…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 26, 2026	AMC	2.14	2.04	-4.7%	44.22	-1.6%	-5.8%	-5.9%	-9.6%	-10.4%	-15.7%	-27.7%	—
Nov 6, 2025	AMC	1.86	2.25	+21.0%	40.66	+0.6%	+4.0%	+7.1%	+10.3%	+16.5%	+14.1%	+17.8%	—
Aug 7, 2025	AMC	1.62	1.68	+3.7%	32.94	+1.1%	+6.0%	+9.7%	+15.0%	+14.9%	+12.8%	+14.6%	—
May 8, 2025	AMC	1.43	1.49	+4.2%	27.27	+8.8%	+5.9%	+8.4%	+9.3%	+6.6%	+7.6%	+11.6%	—
Feb 27, 2025	AMC	1.54	1.77	+14.9%	28.42	+6.7%	+2.2%	+0.1%	-1.3%	+0.2%	+4.9%	+5.0%	—
Nov 7, 2024	AMC	1.59	1.61	+1.3%	34.71	-4.9%	-7.3%	-7.3%	-9.5%	-13.1%	-12.8%	-11.8%	—
Aug 8, 2024	AMC	1.49	1.62	+8.7%	35.32	-2.0%	+0.5%	+0.8%	+3.9%	-2.9%	+0.5%	+3.9%	—
May 9, 2024	AMC	1.47	1.45	-1.4%	37.86	-12.8%	-16.8%	-15.1%	-12.1%	-10.2%	-11.1%	-12.0%	—
Feb 22, 2024	AMC	1.38	1.58	+14.5%	32.81	+5.2%	+10.8%	+11.4%	+12.1%	+11.5%	+11.9%	+22.4%	—
Nov 7, 2023	AMC	1.22	1.34	+9.8%	21.68	+9.8%	+6.6%	+12.5%	+12.9%	+16.2%	+15.8%	+25.4%	—
Aug 3, 2023	AMC	1.22	1.26	+3.3%	22.02	+6.5%	+6.7%	+9.2%	+9.4%	+8.8%	+9.6%	+7.3%	—
May 4, 2023	AMC	1.33	1.32	-0.8%	22.20	+1.3%	+3.2%	+5.5%	+6.0%	+4.0%	+4.2%	-5.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$36.30	$36.31	+0.0%	-2.4%	-4.3%	-8.5%	-8.4%	-7.9%
Mar 19	Needham	Maintains	Buy → Buy	—	$34.80	$35.64	+2.4%	+4.3%	+1.8%	-0.2%	-4.5%	-4.5%
Feb 26	Needham	Maintains	Buy → Buy	—	$45.75	$41.75	-8.7%	-3.3%	-8.9%	-9.1%	-12.6%	-13.4%
Jan 9	Barclays	Maintains	Overweight → Overweight	—	$48.78	$48.77	-0.0%	-6.6%	-1.3%	-3.1%	-4.5%	-3.9%
Jan 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$48.78	$48.77	-0.0%	-6.6%	-1.3%	-3.1%	-4.5%	-3.9%
Jan 8	Needham	Maintains	Buy → Buy	—	$47.26	$47.73	+1.0%	+3.2%	-3.6%	+1.9%	+0.0%	-1.5%
Nov 7	Truist	Maintains	Buy → Buy	—	$40.66	$40.91	+0.6%	+4.0%	+7.1%	+10.3%	+16.5%	+14.1%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.66	$40.91	+0.6%	+4.0%	+7.1%	+10.3%	+16.5%	+14.1%
Oct 28	Needham	Maintains	Buy → Buy	—	$34.82	$34.63	-0.5%	+1.7%	-0.0%	+2.4%	+3.4%	+3.7%
May 9	Piper Sandler	Maintains	Neutral → Neutral	—	$27.27	$29.66	+8.8%	+5.9%	+8.4%	+9.3%	+6.6%	+7.6%
Apr 9	Needham	Maintains	Buy → Buy	—	$25.41	$24.79	-2.4%	+3.8%	-2.9%	+3.5%	+5.2%	+6.7%
Mar 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$30.05	$30.43	+1.3%	+1.7%	+0.3%	-0.3%	-1.6%	-1.1%
Feb 4	Piper Sandler	Maintains	Neutral → Neutral	—	$31.20	$30.81	-1.2%	-0.9%	-1.6%	-0.8%	-1.2%	-2.2%
Jan 10	Needham	Upgrade	Hold → Buy	—	$33.34	$33.92	+1.7%	-1.3%	+1.3%	-0.5%	-1.1%	+0.4%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.34	$33.92	+1.7%	-1.3%	+1.3%	-0.5%	-1.1%	+0.4%
Oct 11	Piper Sandler	Maintains	Neutral → Neutral	—	$36.64	$36.80	+0.4%	+2.9%	+3.7%	+5.2%	+7.4%	+6.2%
Sep 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.24	$38.52	+0.7%	-1.6%	-2.7%	-4.0%	-5.7%	-5.3%
Aug 9	Piper Sandler	Maintains	Neutral → Neutral	—	$35.32	$34.61	-2.0%	+0.5%	+0.8%	+3.9%	-2.9%	+0.5%
Aug 9	Truist	Maintains	Buy → Buy	—	$35.32	$34.61	-2.0%	+0.5%	+0.8%	+3.9%	-2.9%	+0.5%
Jul 30	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$34.89	$36.51	+4.6%	+10.6%	+10.5%	+10.6%	+4.2%	-1.1%
Jun 7	Jefferies	Upgrade	Hold → Buy	—	$31.36	$32.57	+3.9%	+5.8%	+6.2%	+3.9%	+1.7%	+1.9%
May 10	Piper Sandler	Downgrade	Overweight → Neutral	—	$37.86	$33.01	-12.8%	-16.8%	-15.1%	-12.1%	-10.2%	-11.1%
May 10	Needham	Downgrade	Buy → Hold	—	$37.86	$33.01	-12.8%	-16.8%	-15.1%	-12.1%	-10.2%	-11.1%
Apr 11	Needham	Maintains	Buy → Buy	—	$37.99	$37.97	-0.1%	-4.2%	-6.0%	-7.5%	-6.8%	-6.7%
Feb 26	Truist	Maintains	Buy → Buy	—	$36.35	$36.36	+0.0%	+0.6%	+1.2%	+0.6%	+1.0%	+2.1%
Feb 23	Piper Sandler	Maintains	Overweight → Overweight	—	$32.81	$34.50	+5.2%	+10.8%	+11.4%	+12.1%	+11.5%	+11.9%
Feb 2	Needham	Maintains	Buy → Buy	—	$33.47	$33.44	-0.1%	-1.9%	-1.1%	-0.7%	-0.8%	-0.4%
Jan 4	Truist	Maintains	Buy → Buy	—	$33.86	$33.21	-1.9%	-4.5%	-4.6%	-6.3%	-4.7%	-3.6%
Jan 4	Jefferies	Downgrade	Buy → Hold	—	$33.86	$33.21	-1.9%	-4.5%	-4.6%	-6.3%	-4.7%	-3.6%
Jan 4	Needham	Maintains	Buy → Buy	—	$33.86	$33.21	-1.9%	-4.5%	-4.6%	-6.3%	-4.7%	-3.6%
Aug 25	Needham	Maintains	Buy → Buy	—	$23.51	$23.84	+1.4%	+1.5%	-0.1%	+1.3%	+0.3%	-0.4%
Aug 4	Needham	Maintains	Buy → Buy	—	$22.02	$23.46	+6.5%	+6.7%	+9.2%	+9.4%	+8.8%	+9.6%
May 30	Needham	Maintains	Buy → Buy	—	$22.53	$22.58	+0.2%	-3.2%	-2.0%	-0.8%	-4.0%	-6.5%
May 5	Needham	Maintains	Buy → Buy	—	$22.20	$22.49	+1.3%	+3.2%	+5.5%	+6.0%	+4.0%	+4.2%
Apr 19	Needham	Maintains	Buy → Buy	—	$23.14	$23.13	-0.0%	-1.1%	-1.3%	-0.3%	+1.1%	-1.6%
Feb 24	Needham	Maintains	Buy → Buy	—	$26.60	$27.60	+3.8%	+0.9%	+0.8%	-0.3%	+0.7%	+2.3%
Feb 8	Needham	Maintains	Buy → Buy	—	$28.12	$27.44	-2.4%	-4.6%	-5.0%	-4.9%	-4.2%	-4.5%
Jan 5	Needham	Maintains	Buy → Buy	—	$26.98	$27.10	+0.4%	+3.9%	+6.2%	+3.4%	+5.4%	+1.5%
Nov 4	Needham	Maintains	Buy → Buy	—	$18.03	$19.19	+6.4%	+4.5%	+10.8%	+9.4%	+6.6%	+6.8%
Aug 8	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$20.10	$19.41	-3.4%	-3.0%	-3.7%	-1.5%	-4.5%	-6.5%
Apr 6	Needham	Maintains	Buy → Buy	—	$20.08	$20.00	-0.4%	+4.0%	+2.8%	+2.1%	-2.0%	-4.1%
Feb 22	Piper Sandler	Maintains	Overweight → Overweight	—	$21.75	$22.75	+4.6%	+1.9%	+3.4%	-1.6%	-11.0%	-10.5%
Feb 15	Needham	Maintains	Buy → Buy	—	$19.90	$20.71	+4.1%	+9.6%	+12.0%	+10.5%	+9.3%	+11.4%
Feb 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.90	$20.71	+4.1%	+9.6%	+12.0%	+10.5%	+9.3%	+11.4%
Nov 15	Needham	Maintains	Buy → Buy	—	$19.48	$20.50	+5.2%	+2.7%	+2.0%	+0.4%	-2.2%	-3.2%
Nov 5	Needham	Maintains	Buy → Buy	—	$19.35	$18.99	-1.9%	-1.5%	+5.1%	+5.1%	+4.4%	+4.0%
Aug 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.84	$20.81	-16.2%	-17.3%	-19.9%	-23.4%	-24.9%	-26.7%
Aug 6	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$24.84	$20.81	-16.2%	-17.3%	-19.9%	-23.4%	-24.9%	-26.7%
Aug 6	Needham	Maintains	Buy → Buy	—	$24.84	$20.81	-16.2%	-17.3%	-19.9%	-23.4%	-24.9%	-26.7%
Jan 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.69	$22.45	+3.5%	-2.4%	-0.6%	+0.6%	+2.8%	+10.9%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

The departure of Dr. Fallon from the board removes a director whose contributions were significant, potentially signaling governance changes or internal disagreements that investors should monitor for strategic direction shifts.

Apr 7

8-K · 1.01 !! High

Unknown — 8-K 1.01: Material Agreement

Collplant signed a $24M agreement with Corium, likely for technology licensing or partnership, potentially unlocking new revenue streams and validating its regenerative medicine platform's commercial value.

Mar 19

8-K · 7.01 ! Medium

Collegium Pharmaceutical, Inc. -- 8-K 7.01: Regulation FD Disclosure

Collegium Pharmaceutical furnished an investor presentation under Regulation FD Disclosure, suggesting the company is providing material non-public information to investors that must now be disclosed publicly.

Feb 26

Data updated apr 25, 2026 2:36am · Source: massive.com